IL15 and breast carcinoma: Overall, using an orthotopic murine luminal B breast cancer model, our study identifies the immune signature of regressing tumors and the localization and in situ distribution of IL-15 complexes and anti-PD-1 mAb within immune cells in regressing and non-regressing luminal B tumors.